Biotechnology

Wednesday May 15, 2024 - 11:28 am

InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Releases Financial Report, Business Update for Q1 2024

Longeveron (NASDAQ: LGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, is reporting financial results and a business update for the first quarter of 2024, the period ended March 31, 2024. Highlights of the report include that the company’s phase 2b clinical trial evaluating Lomecel-B(TM) in rare pediatric disease hypoplastic left heart syndrome (“HLHS”) is on track for completing…

Wednesday May 15, 2024 - 11:20 am

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Q1 2024 Financial Results, Provides Business Update

Predictive Oncology (NASDAQ: POAI) is a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development. The company today announced financial and operating results for the quarter ended March 31, 2024, and provided a corporate update. The company reported a net loss of approximately…

Wednesday May 15, 2024 - 10:30 am

InvestorNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Announces Q1 2024 Results

DarioHealth (NASDAQ: DRIO), a leader in the global digital health market, today reported financial results for the first quarter 2024. Among the highlights, the company reported first quarter revenue of $5.8 million, reflecting a 59% increase over the fourth quarter of 2023 primarily resulting from an increase in B2B2C revenues. “In the first quarter, our revenue increased by 59% over the fourth quarter 2023 reflecting…

Tuesday May 14, 2024 - 1:07 pm

InvestorNewsBreaks – Rejuvine Life Sciences Launches Crowdfunding Campaign

Rejuvine Life, dedicated to developing natural healthcare solutions, today announced a crowdfunding campaign to expand its U.S. product line and advance diabetes research management. According to the announcement, the company utilizes natural resources to support the millions worldwide living with diabetes. Skordo Plus, Rejuvine Life’s leading product, is a garlic-based supplement designed to help regulate blood sugar levels and enhance overall well-being. “We believe everyone…

Tuesday May 14, 2024 - 12:49 pm

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Participation Schedule for Upcoming May Conferences

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today announced that it will participate in three investor conferences in May. Clene will participate in one-on-one meetings at the Mizuho Neuroscience Summit 2024, the Benchmark 2024 Healthcare House Call Virtual…

Tuesday May 14, 2024 - 12:35 pm

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Participation in FDA Event Exploring Emerging Therapeutic Interest in Ketamine

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced its planned attendance at a hybrid public meeting on June 27, 2024. The meeting will be hosted by the U.S. Food and Drug Administration (“FDA”) in partnership with the Reagan-Udall Foundation for the FDA. The virtual and in-person event,…

Tuesday May 14, 2024 - 12:23 pm

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q3 Fiscal 2024 Financial Results, Business Update

InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates, is reporting on its financial and business results for the third quarter of 2024, the period that ended March 31, 2024. Business highlights included the announcement of preclinical data supporting both the company’s INM-901 and INM-089 programs; the continued development of its ALZ program, with long-term…

Tuesday May 14, 2024 - 12:02 pm

InvestorNewsBreaks – Safety Shot Inc. (NASDAQ: SHOT) Highlights Innovation in Beverage Wellness, Expands to the Northeast

Safety Shot (NASDAQ: SHOT) is a pioneering force in the beverage landscape, introducing a groundbreaking solution designed to swiftly alleviate the effects of alcohol consumption. With its patented formula, Safety Shot accelerates the detoxification process, offering consumers a rapid path to relief and reshaping nocturnal revelries and morning recoveries. By leveraging a carefully crafted blend of scientifically proven ingredients, including vitamins, minerals and nootropics, Safety…

Tuesday May 14, 2024 - 11:00 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO Slated to Present at Upcoming Alliance Global Partners Healthcare Company Showcase

Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, will be participating in an upcoming virtual Alliance Global Partners Healthcare Company Showcase. The event is scheduled for May 21, 2024. According to the announcement, Cybin CEO Doug Drysdale will be presenting a fireside chat during the showcase; his presentation…

Tuesday May 14, 2024 - 9:45 am

InvestorNewsBreaks – Astrotech Corp. (NASDAQ: ASTC) Releases Q3 202 Financial Report

Astrotech (NASDAQ: ASTC), an innovative science and technology company, is reporting its financial results for the third quarter of fiscal year 2024, for the period ended March 31, 2024. Highlights of the report include the company’s strong consolidated balance sheet showing $34.7 million in cash and liquid investments; revenue for the year-to-date coming in at $1.6 million; year-to-date gross margin increased to 45% from 37% through…

Monday May 13, 2024 - 11:18 am

InvestorNewsBreaks – HeartBeam Inc.’s (NASDAQ: BEAT) AIMIGo(TM) Recognized as ‘Best New ECG Technology Solution’ in Awards Program

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has announced that its HeartBeam AIMIGo(TM) was selected as winner of the “Best New ECG Technology Solution” award in the 8th annual MedTech Breakthrough Awards program. Conducted by MedTech Breakthrough, an independent market intelligence organization, the awards program recognizes the top companies, technologies and products in the…

Monday May 13, 2024 - 9:26 am

InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Releases Planned Transitions for Board of Directors

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, is reporting changes on its board of directors. The following transitions on the board have been announced: Richard Kender, retired SVP of business development and corporate licensing for Merck & Co. Inc., has been appointed to the board; Dr. Roger Hajjar, former head of R&D at Ring Therapeutics, and…

Friday May 10, 2024 - 1:57 pm

InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Featured in Upcoming RedChip Small, Big Money(TM) Show

Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, is featured in an upcoming interview on the RedChip Small Stocks, Big Money(TM) show. During the program, which is scheduled to air on Bloomberg TV this Saturday, May 11, at 7 p.m. ET, Gareth Sheridan, Founder and CEO of Nutriband, will provide a corporate update. To access the interview, visit https://ibn.fm/Nhihy To…

Friday May 10, 2024 - 9:14 am

InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q1 2024 Financial, Operational Report

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, is reporting on its financial and operational results for first quarter 2024, for the period ended March 31, 2024. Highlights of the report include the 510(k) submission for BEAT’s AIMIGo(TM) system for review by the U.S. Food and Drug Administration (“FDA”); presubmission meetings being held with the…

Thursday May 09, 2024 - 3:35 pm

InvestorNewsBreaks – Astrotech Corporation (NASDAQ: ASTC) Filling Void in Hemp and Cannabis Market

Astrotech (NASDAQ: ASTC), a science and technology development and commercialization company, and its wholly owned subsidiary, AgLAB Inc., have developed a mass spectrometer designed for use in the hemp and cannabis market. “During the process of converting cannabis biomass into distillate, valuable cannabinoids are typically lost, resulting in reduced profits. AgLAB’s Maximum Value Processing (‘MVP’) method uses the powerful AgLAB-1000-D2 mass spectrometer to test and…

Wednesday May 08, 2024 - 12:44 pm

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Releases Q1 2024 Financial Numbers, Operation Highlights

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., are reporting on first-quarter 2024 financial results and operating highlights for its CNM-Au8 clinical program for amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). Clene Nanomedicine is a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases. Highlights of the report include the news that data from the long-term extension of…

Tuesday May 07, 2024 - 11:57 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Marks Important Step in Advancing Lucid-21-302

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces the submission to ethics of a trial. Entitled “A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants,” the clinical trial application is…

Tuesday May 07, 2024 - 10:24 am

InvestorNewsBreaks – PaxMedica Inc. (PXMD) Continues Advancement of PAX-101 Regulatory Strategy

PaxMedica (OTC: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has issued a corporate update in light of its transition off the NASDAQ stock market, emphasizing this change will not affect the company’s commitment to advancing treatments for neurological disorders. “Our determination to progress with the NDA submission for PAX-101 remains unaffected, as does our commitment to our clinical program to further…

Monday May 06, 2024 - 2:56 pm

InvestorNewsBreaks – Aileron Therapeutics Inc. (NASDAQ: ALRN) Closes Underwritten Registered Direct Offering

Aileron Therapeutics (NASDAQ: ALRN) is a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications. The company has announced the closing of its underwritten registered direct offering priced at-the-market under Nasdaq rules of 4,273,505 shares of its common stock and accompanying warrants to purchase an aggregate of 4,273,505 shares of common stock. Aileron…

Monday May 06, 2024 - 11:56 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Issues Corporate Update, Eyes Runway for Upcoming Clinical Milestones

Cybin (NYSE American: CYBN) (Cboe CA: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options. The company has provided a corporate update highlighting recent clinical accomplishments and key upcoming catalysts across its development pipeline. “With the prevalence and burden of mental health conditions at an all-time high, there is an urgent and growing need…

Monday May 06, 2024 - 10:13 am

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation at Upcoming EF Hutton Global Conference

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, will be represented at this month’s EF Hutton Annual Global Conference. According to the announcement, key company officials will be attending the event, which will be held in New York City on May 15, 2024. Members of the Processa Pharmaceuticals management team will…

Friday May 03, 2024 - 10:49 am

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Securities Purchase Agreements, Anticipates Receiving Approximately $4.2M from Placement

Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, has entered into securities purchase agreements. The agreements are for the purchase and sale of 4,186 shares of the Company’s Series C-1 Convertible Preferred Stock and 4,186 shares of the Company’s D-1 Preferred Stock, as well as warrants to purchase approximately 1.65 million shares of common stock in a private placement. According…

Wednesday May 01, 2024 - 10:59 am

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation at Upcoming Investor, Industry Events

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be participating at two conferences during May. According to the announcement, Genprex CFO Ryan Confer will be presenting at the Sidoti Microcap Conference, which is held May 8–9, 2024. Confer’s presentation is slated to begin at 3:15 p.m. ET on May 8. The virtual presentation…

Wednesday May 01, 2024 - 10:15 am

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Partners with FluGen to Develop First-of-Its-Kind Intranasal Flu Vaccine for Global Distribution

Predictive Oncology (NASDAQ: POAI), a leader in artificial-intelligence (“AI”)-driven drug discovery and biologics, is partnering with FluGen to bring a first-of-its-kind intranasal flu vaccine to market. According to the announcement, the partnership is part of a $6.2 million phase 2B grant awarded by the United States Department of Defense (“DoD”). The collaboration involves members of the Predictive Oncology biologics team focusing on developing a formulation…

Monday Apr 29, 2024 - 12:36 pm

InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Presenting at This Week’s Planet MicroCap Showcase

Longeveron (NASDAQ: LGVN), a clinical-stage, biotechnology company developing regenerative medicines, is one of 96 companies slated to participate at the Planet MicroCap Showcase: VEGAS. The three-day event begins in Las Vegas tomorrow and runs through May 2, 2024. The event kicks off with “MicroCap Investing Workshop,” which features widely recognized financial influencers, investors, fund managers and key opinion leaders. On Wednesday, Longeveron is slated to…

Friday Apr 26, 2024 - 9:58 am

InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Featured in Latest Bell2Bell Podcast Release

PaxMedica (NASDAQ: PXMD), a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, was featured in the latest episode of The Bell2Bell Podcast as part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. Howard Weisman, CEO of PaxMedica, and Dr. Marshal Lemerani, Program Manager at the Malawi Ministry of Health, joined the program to discuss the urgent request for…

Friday Apr 26, 2024 - 9:32 am

InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) to Participate in Upcoming Planet MicroCap Showcase

Longeveron (NASDAQ: LGVN), a clinical-stage, biotechnology company developing regenerative medicines, will be presenting at next month’s Planet MicroCap Showcase. The conference is slated for May 1–2, 2024, in Las Vegas. According to the announcement, Longeveron’s presentation is scheduled to begin at 4:30 p.m. PT. An archived copy of the webcast will be available on the company’s website following the presentation. In addition, Longeveron officials will…

Thursday Apr 25, 2024 - 12:13 pm

InvestorNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Reports on Two Studies Evaluating Impact of Digital Behavioral Health Program for Teens

DarioHealth (NASDAQ: DRIO), a leader in the global digital health market, has new research being published in the leading peer-reviewed journal for digital health and medicine, the “Journal of Internet Medicine.” The research is based on a quasi-randomized study that demonstrates the value of Dario's integrated approach in providing a solution for members to manage diabetes, prediabetes, blood pressure, weight and the use of a GLP-1.…

Thursday Apr 25, 2024 - 11:46 am

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Schedules Conference Call to Discuss Q1 2024 Results

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, today announced that it will hold a conference call on Thursday, May 9, 2024, at 4:30 p.m. Eastern Time to discuss its results for the first quarter ended March 31, 2024. In addition, the company will provide regulatory updates, review…

Thursday Apr 25, 2024 - 11:07 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation at the 27th Annual Milken Institute Global Conference

Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, is announcing its participation at the 27th Annual Milken Institute Global Conference, set to take place May 5-8, 2024, at the Beverly Hilton in Los Angeles. According to the announcement, Doug Drysdale, Cybin CEO, will appear on a panel entitled “Collaborating for Improved Mental Health,” on…

Thursday Apr 25, 2024 - 9:39 am

InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Engages IBN for Corporate Communications Expertise

Nutriband (NASDAQ: NTRB, NTRBW), a pharmaceutical company with a special focus on transdermal technologies, today announced that it has selected IBN, a multifaceted financial news and publishing company for private and public entities, to assist with its corporate communications initiatives. According to the announcement, Nutriband’s AVERSA(TM) technology can be incorporated into any transdermal patch and includes aversive agents to prevent abuse, diversion, misuse and accidental…

Thursday Apr 25, 2024 - 9:10 am

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Abstract to Be Presented Next Month at ASCO Annual Meeting

Predictive Oncology (NASDAQ: POAI), a leader in artificial-intelligence (“AI”)-driven drug discovery and biologics, announced that its abstract has been accepted for presentation at the upcoming American Society of Clinical Oncology (“ASCO”) annual meeting. This year’s meeting is slated for May 31–June 4, 2024, in Chicago. According to the company, the abstract contains data and results gathered from a recent study completed through a collaboration between…

Wednesday Apr 24, 2024 - 12:03 pm

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Update on Plan of Arrangement with Exopharm Limited

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that shareholders of Exopharm Limited ACN 163 765 991 approved a previously announced plan of arrangement between Exopharm Limited and Tryp (the “parties”). The announcement confirmed that all conditions precedent to the completion of the arrangement…

Wednesday Apr 24, 2024 - 11:41 am

InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Closes $8.4M Private Placement

Nutriband (NASDAQ: NTRB, NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has closed an $8.4 million private placement to fund the commercial development program for its lead product, AVERSA(TM) Fentanyl. AVERSA Fentanyl has the potential to be the world’s first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure…

Wednesday Apr 24, 2024 - 9:20 am

InvestorNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Completes Key Step in Preparation of PAX-101 for NDA Submission to FDA

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has made a key announcement regarding the development of its proprietary PAX-101, an IV formulation of suramin. According to the announcement, the company has completed execution of three pivotal registration/validation batches of PAX-101. The company noted that the completion is an “important milestone” in enabling a New Drug Application (“NDA”) submission to…

Tuesday Apr 23, 2024 - 1:54 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at LSX World Congress 2024

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced that its Chief Executive Officer John Climaco will present at the LSX World Congress 2024. Climaco is slated to present at 4:15 PM (GMT+1) on Monday, April 29, 2024, at the event taking place in London, England.…

Tuesday Apr 23, 2024 - 12:33 pm

InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Responds to Emergency Request for IV Suramin, Commits to Provide Immediate Access to PAX-101

PaxMedica (NASDAQ: PXMD), a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, expects to take immediate action in response to an urgent request for IV suramin from the Ministry of Health (“MOH”) of Malawi, a country in east Africa. The request seeks emergency access to PaxMedica’s recently completed registration batches of PAX-101 (“IV suramin”) to address the critical shortage of medications required to…

Tuesday Apr 23, 2024 - 9:56 am

InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Enters Exclusive Supplier Agreement with Major Sports Brand Licensee

Nutriband (NASDAQ: NTRB, NTRBW) today announced that following its engagement by Fit For Life Group (“FFL”), a major brand license holder, on April 19, 2024, the companies fully executed an exclusive supplier agreement for FFL’s new product launch under one of its top brands. According to the announcement, Nutriband’s wholly owned contract manufacturing subsidiary, Active Intelligence, will act as manufacturer. Founded in 2016, FFL has…

Friday Apr 19, 2024 - 1:34 pm

InvestorNewsBreaks – Astiva Health Is Redefining Senior Healthcare

Astiva Health, a leading healthcare provider that specializes in delivering personalized and comprehensive healthcare solutions to diverse communities, is pioneering transformative healthcare for seniors, with a focus on enhancing mobility and promoting independence. “Central to Astiva Health’s mission is empowering seniors to engage actively in their healthcare decisions, supporting their flourishing in later years… Astiva Health is committed to empowering seniors through customized exercise programs…

Friday Apr 19, 2024 - 9:13 am

InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Closes on Multimillion-Dollar Warrant Exercise Offering, Public Offering

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has closed on its warrant exercise offering. According to the announcement, the exercise comprised certain existing warrants to purchase 2,399,744 shares of LGVN Class A common stock; the warrants were originally issued in October 2023 and April…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions